In Reply We thank Skelin and colleagues for their interest in our prospective population-based studies of aspirin use and the risk of incident hepatocellular carcinoma (HCC)1 and ovarian cancer.2 As Skelin asserts, our site-specific findings should be examined in conjunction with research on total cancer incidence. Our prior study of these same cohorts found that regular (≥325 mg, ≥2 times per week) vs nonregular aspirin use was associated with a hazard ratio of 0.97 (95% CI, 0.94-0.99) for overall cancer.3 A meta-analysis of 34 randomized clinical trials (RCTs) of aspirin and total cancer death reported similar results,4 so we believe population-based research of aspirin and site-specific cancer incidence remains valid and important.
Simon TG, Barnard ME, Chan AT. Aspirin Use and the Risk of Cancer—In Reply. JAMA Oncol. 2019;5(6):913. doi:10.1001/jamaoncol.2019.0633
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.